To determine whether mesothelin could be an effective therapeutic target for pancreatic cancer, the effect of mesothelin shRNA on cell growth of the pancreatic cancer cells was examined in ASPC-1 and CaPan-1/2 pancreatic cancer cells. The gene discussed is MSLN; the disease is familial pancreatic carcinoma.